Hereditary ovarian cancers are caused by mutations in many genes. For this reason, testing for only one hereditary cancer syndrome may lead to missed mutations. The Myriad myRisk® test solves this dilemma by evaluating multiple clinically-significant genes and detecting more people who may be at risk for hereditary ovarian cancer.
Approximately 10-15 percent of ovarian cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. Women who carry a mutation in either of these genes have a condition called Hereditary Breast and Ovarian Cancer (HBOC) syndrome.1-3 They have an up to 63 percent risk of developing ovarian cancer by age 70.4 In addition, mutation carriers who have already been diagnosed with cancer have a significantly increased risk of developing a second cancer in the future. Patients with Lynch syndrome are also at higher risk of developing ovarian, colon and endometrial cancers. Myriad offers genetic testing that can be used to identify people who carry a BRCA1 or BRCA2 gene mutation or have Lynch syndrome.
Assessing Your Risk
In order to assess your risk of carrying a BRCA1, BRCA2 or other gene mutation, your healthcare professional may ask you questions about your personal and family history. Knowing your medical history helps your healthcare professional determine whether you might be an appropriate candidate for genetic testing, which can provide an assessment of your risk of developing ovarian and/or breast cancer, or whether you might have Lynch syndrome.
To help you determine whether you may benefit from hereditary cancer genetic testing, take the Myriad Hereditary Cancer Quiz. This quiz can help you get the information you need to discuss your risk of cancer with your healthcare professional.
Risk Factors for Ovarian Cancer
Knowing your potential risk for HBOC can help you and your healthcare professional make better, more informed decisions about your health, before the onset of cancer or before a second cancer has a chance to develop. Genetic testing for hereditary breast and ovarian cancer with the Myriad myRisk® Hereditary Cancer test should be considered if:*
- Have had breast cancer at age 50 or younger
- Have ever had ovarian cancer
- Are male and have had breast cancer at any age
- Are of Ashkenazi Jewish descent and have a personal or family history of breast, ovarian, prostate or pancreatic cancer
- Has had two breast cancers in the same person or on the same side of the family
- Has had someone diagnosed with triple negative breast cancer at any age
- Has had pancreatic cancer and an HBOC-associated** cancer in the same person or on the same side of the family
- Has three or more family members with breast cancer on the same side of the family
- Has had a previously identified BRCA1, BRCA2 or other gene mutation in the family
Using Hereditary Cancer Testing to Reduce Your Risk of Ovarian Cancer
If the Myriad myRisk® Hereditary Cancer test confirms the presence of a BRCA1 or BRCA2 mutation or a mutation in another gene associated with ovarian cancer risk, the following medical management options may help reduce cancer risk and may either prevent or delay the onset of cancer or detect cancer at an earlier, more treatable stage:†
- Increased surveillance for ovarian, breast and/or other cancers associated with the gene mtutation, such as starting cancer screening at an earlier age and using breast MRI in addition to mammography.
- Risk-reducing medications.
- Preventive surgery, such as mastectomy or oophorectomy (surgical removal of the ovaries).
Using the results of the Myriad myRisk® Hereditary Cancer test, your healthcare professional can help you move forward with the right action plan for your particular risk. Your test results can also help your family members learn and understand more about inherited cancer risk and how it may affect them.
*Assessment criteria are based on medical society guidelines.
**HBOC-associated cancers are breast, ovarian, prostate and pancreatic.
†Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
1. Claus EB, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
2. Pal T, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104(12):2807-2816.
3. Risch H, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001: 68:700-710.
4. Easton DF, et al. Breast and ovarian cancer incidence in BRCA1- mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 56:265-71. PMID: 7825587.